Application of nestorone to preparation of drugs for treating Parkinson's disease

A Parkinson's disease and drug technology, applied in the fields of neurology and pharmacology, can solve problems such as Nestorone and Parkinson's disease research reports that have not been seen, and achieve the effect of improving and treating curative effect, with less toxic and side effects

Inactive Publication Date: 2012-09-26
温州医学院附属第二医院 +1
View PDF1 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

But there is no research report about Nestorone and Parkinson's disease except this research institute

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of nestorone to preparation of drugs for treating Parkinson's disease
  • Application of nestorone to preparation of drugs for treating Parkinson's disease
  • Application of nestorone to preparation of drugs for treating Parkinson's disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0011] Example 1: MPTP was used to establish a mouse model of Parkinson's disease, and Nestorone was injected subcutaneously for pretreatment before modeling and intervention after modeling

[0012] 84 C57 mice, weighing 18g-25g, were randomly divided into 7 groups. Normal control group (Con): subcutaneous injection of normal saline (0.01ml·g) twice a day -1 ) A total of 11 days, on the 6th day, another intraperitoneal injection of normal saline (0.01ml·g -1 ) 4 times; model group (Mod): subcutaneous injection of normal saline (0.01ml·g) twice a day -1 ) A total of 11 days, the 6th day of intraperitoneal injection of MPTP; solvent group (Veh): twice daily subcutaneous injection of 10% ethanol (0.01ml·g -1 ) A total of 11 days, the 6th day of intraperitoneal injection of MPTP; Nestorone low dose group (0.08mg·kg -1 ·D -1 , Nes L): Nestorone 0.04mg·kg subcutaneously injected twice daily -1 A total of 11 days, the 6th day of intraperitoneal injection of MPTP; Nestorone high-dose group...

Embodiment 2

[0014] Example 2: Climbing pole experiment to detect the movement coordination ability of mice

[0015] A metal climbing rod with a height of 50 cm, a diameter of 1 cm, and a rough surface were made before the model, five days after the injection, and five days after the drug. The rod was vertically fixed on the base. The top of the rod was a small wooden ball with a diameter of 2.5 cm. The rod and ball are tightly wrapped with gauze to prevent the mice from slipping. According to the method described therein and improved, the time is measured 1 day before administration, 1 day after MPTP administration, and 1 day after the end of administration. The time is measured by placing the mouse's head horizontally on the ball on the top of the rod, and the time from the forelimbs beginning to touch the rod body until the forelimbs touch the ground. .

[0016] The results showed that after modeling, the climbing time of the Mod group and the Veh group was significantly longer than that of...

Embodiment 3

[0020] Example 3: Detecting the expression of TH and GFAP in the substantia nigra of mice by immunohistochemistry

[0021] First, give the model according to Example 4, and after the pole climbing test on the 12th day according to Example 5, intraperitoneal injection of 0.01ml·g -1 Mice in each group were anesthetized with 8% (W / V) chloral hydrate. Six mice were randomly selected to open the chest after the consciousness disappeared, and the left ventricle-aorta was intubated, and the mice were perfused with normal saline and 4% paraformaldehyde (4℃). If the mice’s liver was white and the limbs were stiff, the perfusion was successful. The brain was immersed in 4% paraformaldehyde and fixed, embedded in paraffin, and sectioned. After routine deparaffinization of brain tissue sections in water, immersion in PBS; high pressure heat repair of tissue antigen in citric acid repair solution; PBS washing; 3% hydrogen peroxide blocking for 20 minutes; PBS washing; adding TH antibody (1:1...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides application of nestorone (16-methylene-17alpha-acetyloxy-19-norpregn-4-ene-3, 20-dione, nes) to preparation of neuroprotective drugs for improving and treating Parkinson's disease. The prepared drugs contain preparation-allowable drug excipients or carriers. The drugs can be made into the forms of liquid, particle, controlled release formulation, electuary, tablet or capsule. In terms of cells, the neuroprotective drugs and application thereof using nestorone to improve and treat Parkinson's disease are demonstrated, and the curative effect of the neuroprotective drugs compared with progesterone on improving and treating Parkinson's disease is better, and the toxic and side effects to nervous systems are low.

Description

Technical field [0001] The invention belongs to the field of neurology and pharmacology, and relates to Nestorone (16-methylene-17α-acetoxy-19-anocarbo-pregn-4-ene-3,20-dione, Nes) in the preparation of therapeutic paraffin Use in medicine for Kingson's disease. Background technique [0002] The incidence of Parkinson's disease (Parkinson's disease, PD) is also on the rise, and it is currently recognized as the second largest degenerative disease of the central nervous system in the elderly. The main pathological change of Parkinson's disease is the progressive degeneration and necrosis of dopamine (DA) neurons in the substantia nigra compact part of the midbrain, which causes a significant decrease in the level of the neurotransmitter dopamine in the substantia nigra-striatal pathway. Epidemiological research, pathological analysis and biochemical identification indicate that 95% of Parkinson's disease is sporadic and delayed [Tanner CM. Adv Neurol 2003, 91: 133-142]. In addit...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/57A61P25/16
Inventor 葛仁山连庆泉林函苏颖李晓珩金元
Owner 温州医学院附属第二医院
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap